{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:52:40Z","timestamp":1792497160179,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Histone deacetylase (HDAC) inhibitors have shown therapeutic promise in various cancers, including hepatocellular carcinoma (HCC), due to their ability to regulate cell proliferation, differentiation, and apoptosis. However, their role in metabolic reprogramming and differentiation therapy in HCC remains underexplored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study investigated the effects of the HDAC inhibitor MS275 on HCC cells <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Cell viability, differentiation marker expression, cell cycle distribution, metabolic activity, and reactive oxygen species (ROS) production were evaluated using CCK-8 assays, qRT-PCR, flow cytometry, Seahorse metabolic analysis, and western blotting. A xenograft mouse model was used to validate <jats:italic>in vivo<\/jats:italic> efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MS275 significantly suppressed HCC cell proliferation by inducing G0\/G1 phase arrest without triggering apoptosis. MS275 also upregulated hepatocyte-specific markers (GLUL, HNF1A, HNF3A), indicating that it promoted differentiation. Mechanistically, MS275 reprogrammed cellular metabolism by enhancing oxidative phosphorylation and reducing glycolysis, accompanied by increased expression of the metabolic enzyme PKM1. This metabolic shift led to elevated ROS production, which was essential for MS275-induced differentiation. Knockdown of PKM1 abolished both the differentiation and anti-proliferative effects. <jats:italic>In vivo<\/jats:italic>, MS275 significantly reduced tumor growth and promoted differentiation without systemic toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MS275 suppresses HCC cell proliferation and induces hepatocyte-like differentiation through PKM1-mediated metabolic reprogramming and ROS signaling. These findings support the potential of MS275 as a differentiation-based therapeutic strategy for HCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1623211","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:14:04Z","timestamp":1757996044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"B1","volume-title":"Hepatocellular Carcinoma","author":"Asafo-Agyei","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.livres.2023.11.004","article-title":"Hepatocellular carcinoma recurrence: Predictors and management","volume":"7","author":"Abdelhamed","year":"2023","journal-title":"Liver Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v11.i3.261","article-title":"Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation","volume":"11","author":"Filgueira","year":"2019","journal-title":"World J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2021.1976142","article-title":"Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics","volume":"25","author":"Wang","year":"2021","journal-title":"Expert Opin Ther Targets"},{"key":"B6","doi-asserted-by":"publisher","first-page":"216744","DOI":"10.1016\/j.canlet.2024.216744","article-title":"Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: Emphasis on cell death mechanism crosstalk","volume":"588","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.513","article-title":"Dysregulation of apoptosis in hepatocellular carcinoma cells","volume":"15","author":"Fabregat","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41420-024-02116-x","article-title":"Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101587","article-title":"Histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro","volume":"11","author":"Freese","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1656-6","article-title":"Histone deacetylase inhibitors and cell death","volume":"71","author":"Zhang","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10699","article-title":"Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest\/apoptosis and hepatocyte differentiation in human hepatoma cells","volume":"103","author":"Yamashita","year":"2003","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.93375","article-title":"HDAC inhibition sensitize hepatocellular carcinoma to lenvatinib via suppressing AKT activation","volume":"20","author":"Yan","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0526","article-title":"Entinostat: a promising treatment option for patients with advanced breast cancer","volume":"13","author":"Connolly","year":"2017","journal-title":"Future Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00262-025-04004-4","article-title":"MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer","volume":"74","author":"Tang","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1290","article-title":"Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL","volume":"21","author":"Stubbs","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B18","article-title":"The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1\/WAF1 1","volume":"63","author":"Rosato","year":"2003","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/2047-783X-18-61","article-title":"Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells","volume":"18","author":"Xiao","year":"2013","journal-title":"Eur J Med Res"},{"key":"B20","article-title":"The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines","volume":"20","author":"Gahr","year":"2008","journal-title":"Oncol Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.188","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.043","article-title":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study","volume":"65","author":"Bitzer","year":"2016","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.05.001","article-title":"Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149","volume":"17","author":"He","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203513","article-title":"Insights into metabolic reprogramming in tumor evolution and therapy","volume":"16","author":"Chiu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1545086","article-title":"Metabolic reprogramming of glucose: the metabolic basis for the occurrence and development of hepatocellular carcinoma","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.31083\/j.fbl2905178","article-title":"Research progress of warburg effect in hepatocellular carcinoma","volume":"29","author":"Yang","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B27","article-title":"Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models","volume":"35","author":"Bracker","year":"2009","journal-title":"Int J Oncol"},{"key":"B28","article-title":"HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells","volume":"15","author":"Yar Saglam","year":"2016","journal-title":"EXCLI J"},{"key":"B29","article-title":"Analysis of cell cycle by flow cytometry","volume":"281","author":"Pozarowski","year":"2004","journal-title":"Methods Mol Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.23268","article-title":"A method permissive to fixation and permeabilization for the multiparametric analysis of apoptotic and necrotic cell phenotype by flow cytometry","volume":"91","author":"Mariotti","year":"2017","journal-title":"Cytometry A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41419-023-05611-8","article-title":"Differential regulation of H3K9\/H3K14 acetylation by small molecules drives neuron-fate-induction of glioma cell","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv029","article-title":"The class I-specific HDAC inhibitor MS-275 decreases motivation to consume alcohol and relapse in heavy drinking rats","volume":"18","author":"Jeanblanc","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091301","article-title":"Suberoylanilide hydroxamic acid (SAHA) is a driver molecule of neuroplasticity: implication for neurological diseases","volume":"13","author":"Verrillo","year":"2023","journal-title":"Biomolecules"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2008.02.014","article-title":"Role of dichloroacetate in the treatment of genetic mitochondrial diseases","volume":"60","author":"Stacpoole","year":"2008","journal-title":"Adv Drug Delivery Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20130282","article-title":"ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors","volume":"454","author":"Halasi","year":"2013","journal-title":"Biochem J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.1038\/s41598-022-12827-9","article-title":"Pyruvate kinase M1 regulates butyrate metabolism in cancerous colonocytes","volume":"12","author":"Park","year":"2022","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604295","article-title":"MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN\/66\u20131 in hormone-insensitive PC-3 prostate cancer cells and tumours","volume":"98","author":"Khandelwal","year":"2008","journal-title":"Br J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12876-022-02101-7","article-title":"MS275 as Class I HDAC inhibitor displayed therapeutic potential on Malignant ascites by iTRAQ-based quantitative proteomic analysis","volume":"22","author":"Du","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/modpathol.3800121","article-title":"Distinguishing well-differentiated hepatocellular carcinoma from benign liver by the physical features of fine-needle aspirates","volume":"17","author":"Yang","year":"2004","journal-title":"Mod Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1271381","article-title":"Characterization and therapeutic perspectives of differentiation-inducing therapy in Malignant tumors","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Genet"},{"key":"B41","article-title":"Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications","volume":"12","author":"Chao","year":"2020","journal-title":"Am J Transl Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1159\/000517992","article-title":"The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size","volume":"10","author":"Shinkawa","year":"2021","journal-title":"Liver Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.037","article-title":"The Anti-Warburg Effect Elicited by the cAMP-PGC1alpha Pathway Drives Differentiation of Glioblastoma Cells into Astrocytes","volume":"18","author":"Xing","year":"2017","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1225578","DOI":"10.1155\/2022\/1225578","article-title":"ROS: basic concepts, sources, cellular signaling, and its implications in aging pathways","volume":"2022","author":"de Almeida","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41419-019-1587-0","article-title":"R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00764-w","article-title":"Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications","volume":"31","author":"Safri","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198911","article-title":"Differentiation therapy of leukemia: 3 decades of development","volume":"113","author":"Nowak","year":"2009","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2016.04.006","article-title":"Hepatocellular carcinoma treatment with sorafenib: real-life evaluation of prognostic factors and a practical clue for patient management","volume":"23","author":"Cardoso","year":"2016","journal-title":"GE Port J Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol Sin"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1623211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:14:05Z","timestamp":1757996045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1623211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2025.1623211"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1623211","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1623211"}}